News | Drug-Eluting Balloons | November 10, 2021

First-in-man Study Shows Effectiveness of of Biolimus Drug-coated Balloon in Small Coronary Vessels

BIO-RISE CHINA study compares Palin balloon angioplasty to the Biosensors BioRise BA9 coated balloon

Biosensors Rise non-compliant angioplasty balloon

November 10, 2021 — Biosensors International Group Ltd., a developer and manufacturer of innovative medical devices, announced the results of the BIO-RISE CHINA study, sponsored by its sister company, JW Medical Systems Ltd. (Shangdong, China). BIO-RISE CHINA is a multi-center, randomized controlled, superiority trial performed in 10 centers across China under the leadership of Prof. Han Yaling, principal investigator, and co-principal investigators, Dr. Guosheng Fu and Dr Yujie Zhou. This first-in-human study assessed the safety and efficacy of a Biolimus A9 (BA9) coated balloon (DCB) in patients with small vessel coronary artery disease undergoing PCI.

“The excellent results of the BioRise BA9 coated balloon [DCB] in this clinical study mean there is now a new therapeutic option for the treatment of small vessel disease in patients undergoing PCI," Han said.

212 patients were randomized between treatment with the BA9 coated balloon and plain old balloon angioplasty (POBA). The study met its primary end-point by demonstrating a highly statistically significant reduction of late lumen loss with the BA9 coated balloon compared to POBA at nine months (0.16±0.29 mm vs. 0.30±0.35 mm ∆ 0.14 mm; 95% CI -0.23 to -0.05; p = 0.001).

In addition, late lumen enlargement was three times more common with the BA9 coated balloon which was also associated with a trend towards improved clinical outcomes at one year.

This data is the first trial in a series of studies Biosensors and JWMS will conduct worldwide, including the REFORM trial (prospective, randomized, non-inferiority trial to determine the safety and efficacy of the BA9 drug coated balloon for the treatment of in-stent restenosis: first-in-man trial, a head-to-head to study comparing the BioRise DCB with the paclitaxel coated Sequent Please DCB across various centers in Europe.

Related Content

Links to All the TCT 2021 Late-Breaking Clinical Trials


Related Content

News | TCT

September 22, 2022 — The recipient of the TCT 2022 Thomas J. Linnemeier “Spirit of Interventional Cardiology” Young ...

Home September 22, 2022
Home
News | TCT

September 19, 2022 — Puzzle Medical Devices, a provider of hemodynamic support in Heart Failure (HF), was selected as ...

Home September 20, 2022
Home
News | TCT

September 16, 2022 — Edwards Lifesciences Corporation, today announced the company's PASCAL Precision transcatheter ...

Home September 16, 2022
Home
News | TCT

September 16, 2022 — CathWorks announced today the schedule of key events for the company during Cardiovascular Research ...

Home September 16, 2022
Home
News | TCT

September 15, 2022 — The Cardiovascular Research Foundation (CRF) will honor Valentin Fuster, MD, PhD, Director of Mount ...

Home September 15, 2022
Home
News | TCT

September 15, 2022 — Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, will showcase its ...

Home September 15, 2022
Home
Feature | TCT | By Melinda Taschetta-Millane

The Transcatheter Cardiovascular Therapeutics (TCT) conference, which is the Cardiovascular Research Foundation's (CRF) ...

Home September 12, 2022
Home
News | TCT

August 26, 2022 — The Cardiovascular Research Foundation (CRF) and Fogarty Innovation announced today that the program ...

Home August 26, 2022
Home
News | TCT

August 4, 2022 — The Cardiovascular Research Foundation (CRF) has announced the late-breaking clinical science that will ...

Home August 04, 2022
Home
News | TCT

August 2, 2022 — Two significant awards will be presented at TCT 2022, to be held in Boston, Sept. 16-19, 2022. Career ...

Home August 02, 2022
Home
Subscribe Now